Pharma Focus Asia

The University of Texas at El Paso Discovered New Thiophene F-8 for Leukaemia and Lymphoma Cancer Cells

Scientists at The University of Texas at El Paso have discovered a groundbreaking pharmaceutical compound, Thiophene F-8, which has demonstrated efficacy in eliminating leukaemia and lymphoma cancer cells. This discovery holds the potential to revolutionise cancer therapy, introducing innovative treatment approaches.

Thiophene F-8 has shown remarkable success in triggering programmed cell death in leukaemia and lymphoma cells. Essentially, it sends signals to these cells, prompting them to undergo self-destruction, while also hindering the growth of new cancer cells.

The newfound compound's ability to complement existing therapies will be a transformative impact on the lives of patients battling leukaemia and lymphoma.

Leukaemia, a cancer affecting blood cells, and lymphoma, a cancer of the immune system, have been the focus of the researchers' investigation. Their work involved screening various drug compounds to assess their impact on different cancer cell types.

Researchers from The University of Texas at El Paso have discovered a promising pharmaceutical compound named Thiophene F-8 that effectively eliminates leukaemia and lymphoma cancer cells. This breakthrough holds the potential to introduce innovative therapeutic approaches for these types of cancers.


 

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024